Alpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting
April 28 2021 - 4:05PM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for cancer and autoimmune/inflammatory
diseases, today announced an upcoming presentation on NEON-1, the
company’s Phase 1 clinical trial of ALPN-202 monotherapy at the
American Society of Clinical Oncology (ASCO) Virtual Annual
Meeting, scheduled to take place June 4-8, 2021.
Details of the poster presentation are as follows:
Presentation Title:
First-in-human dose escalation of
ALPN-202, a conditional CD28 costimulator and dual checkpoint
inhibitor, in advanced malignancies
Session Title:
Developmental
Therapeutics—Immunotherapy
Date Poster Available:
Friday, June 4th
Abstract Number:
2547
The meeting presentation will update the data shown in the
abstract.
Full abstracts will be available on the ASCO meeting website on
May 19th, 2021 and a copy of the presentation will be available on
June 4th on the Scientific Publications page of Alpine’s
website.
About ALPN-202
ALPN-202 is a first-in-class, conditional CD28 costimulator and
dual checkpoint inhibitor with the potential to improve upon the
efficacy of combined checkpoint inhibition while limiting
significant toxicities. Preclinical studies of ALPN-202 have
successfully demonstrated superior efficacy in tumor models
compared to checkpoint inhibition alone. NEON-1 (NCT04186637), a
Phase 1 study of ALPN-202 in patients with advanced malignancies,
is currently enrolling. Alpine also plans the initiation of NEON-2,
a combination study of ALPN-202 and a PD-1 inhibitor, later this
year.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave
of immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is creating first- or best-in-class
multifunctional immunotherapies via unique protein engineering
technologies to improve patients’ lives. Alpine has entered into
strategic collaborations with leading global biopharmaceutical
companies and has a diverse pipeline of clinical and preclinical
candidates in development. For more information, visit
www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter
and LinkedIn.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology and potential therapies, the timing of and
results from clinical trials and preclinical development
activities, clinical and regulatory objectives and the timing
thereof, expectations regarding the sufficiency of cash combined
with the potential $75 million in pre-option exercise milestones
payable under our option and license agreement with AbbVie to fund
operations through 2023, the potential efficacy, safety profile,
future development plans, addressable market, regulatory success,
and commercial potential of our product candidates, our ability to
achieve milestones in our collaboration with AbbVie, the progress
and potential of our other ongoing development programs, the timing
of our public presentations and potential publication of future
clinical data, the efficacy of our clinical trial designs,
anticipated enrollment in our clinical trials and the timing
thereof, expectations regarding our ongoing collaborations, and our
ability to successfully develop and achieve milestones in our
development programs. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer
to future events or conditions and include words such as “may,”
“will,” “should,” “would,” “expect,” “plan,” “intend,” and other
similar expressions, among others. These forward-looking statements
are based on current assumptions that involve risks, uncertainties,
and other factors that may cause actual results, events, or
developments to be materially different from those expressed or
implied by such forward-looking statements. These risks and
uncertainties, many of which are beyond our control, include, but
are not limited to: the impact of the COVID-19 pandemic on our
business, research and clinical development plans and timelines and
results of operations, including the impact on our clinical trial
sites, collaborators, and contractors who act for or on our behalf,
may be more severe and prolonged than currently anticipated;
clinical trials may not demonstrate safety and efficacy of any of
our product candidates; our ongoing discovery and preclinical
efforts may not yield additional product candidates; our
discovery-stage and preclinical programs may not advance into the
clinic or result in approved products; any of our product
candidates may fail in development, may not receive required
regulatory approvals, or may be delayed to a point where they are
not commercially viable; we may not achieve additional milestones
in our proprietary or partnered programs; the impact of
competition; adverse conditions in the general domestic and global
economic markets; as well as the other risks identified in our
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and we
undertake no obligation to update forward-looking statements, and
readers are cautioned not to place undue reliance on such
forward-looking statements.
“Secreted Immunomodulatory Proteins,” “SIP,” “Transmembrane
Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,” “vIgD” and
the Alpine logo are registered trademarks or trademarks of Alpine
Immune Sciences, Inc. in various jurisdictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210428005033/en/
Alex Sharif Director, Investor Relations and Corporate
Development Alpine Immune Sciences, Inc. 206-788-4545
ir@alpineimmunesciences.com Laurence Watts Managing Director
Gilmartin Group, LLC. 619-916-7620 laurence@gilmartinir.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Sep 2023 to Sep 2024